A Look Inside the Toolbox for BRAF-Mutant Metastatic Melanoma
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, a medical oncologist and chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center in New York, New York, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.
During the Physician’s Education Resource® 18th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® held in January 2022, Postow spoke to a room of peers about this topic. His talk focused on the past, present, and future of BRAF-directed treatment. During the podcast discussion with host, Nichole Tucker of Targeted Oncology™, the discussion was expanding to dive into topics like; the efficacy of FDA-approve BRAF targeted therapies, the most recent FDA approval and its impact, exploring approved agents in new treatment settings, and other key druggable targets in melanoma.
During the talk, Postow also touches on the main clinical questions that oncologists still have about treating patients with BRAF-mutant melanoma and what research is aiming to provide answers in the near future.
Managing Expectations of Treatment for Infiltrative Basal Cell Carcinoma
November 10th 2023In an event comoderated by Michael K. Wong, MD, PhD, FRCPC, and Anokhi Jambusaria, MD, MSCE, the 2 key opinions leaders discussed the hypothetical patient case of an 88-year-old man with a nonhealing ulcer on the lateral aspect of his nose who received a diagnosis of infiltrative basal cell carcinoma.
Read More
Adjuvant Cemiplimab Shows Survival Benefit For Responders in CSCC
October 21st 2023One-year follow-up of the phase 2 study assessing the use of neoadjuvant and adjuvant cemiplimab in patients with cutaneous squamous cell carcinoma shows a promising survival benefit that has led to a wider phase 3 study.
Read More
Addressing Skin Cancer: From Screening to Treatment
May 20th 2023In an interview with Targeted Oncology, Meredith McKean, MD, MPH of Sarah Cannon Research Institute reviewed the recent changes to the U.S. Preventive Services Task Force skin cancer screening guidelines, and discussed advances in the skin cancer treatment paradigm for those who could not prevent the disease.
Read More
